Filing Details

Accession Number:
0001562180-23-001257
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-10 16:42:31
Reporting Period:
2023-02-10
Accepted Time:
2023-02-10 16:42:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1597553 Sage Therapeutics Inc. SAGE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1042021 M Jeffrey Jonas C/O Sage Therapeutics, Inc.
215 First Street
Cambridge MA 02142
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-10 11,643 $0.45 133,624 No 4 M Direct
Common Stock Disposition 2023-02-10 7,805 $44.47 125,819 No 4 S Direct
Common Stock Disposition 2023-02-10 3,838 $44.90 121,981 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to buy) Disposition 2023-02-10 11,643 $0.00 11,643 $0.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-08-12 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. This transaction was executed in multiple trades at prices ranging from $43.81 USD to $44.77 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $44.815 USD to $45.03 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017.